Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M503Revenue $M14.2Net Margin (%)-810.9Z-Score6.3
Enterprise Value $M273EPS $-3.3Operating Margin %-986.7F-Score2
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-810.9Higher ROA y-yY
Price/Book1.810-y EBITDA Growth Rate %-9.1Quick Ratio11.9Cash flow > EarningsN
Price/Sales38.15-y EBITDA Growth Rate %25.2Current Ratio11.9Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-32.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-38.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M41.3ROI % (ttm)-300.9Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
($22.49)
$ 12.18-46%Reduce -52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
($31.64)
$ 12.18-62%Add 2620%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
($25.36)
$ 12.18-52%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
($29.58)
$ 12.18-59%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
($38.37)
$ 12.18-68%Add 56.28%665,274
SRPTAndreas Halvorsen 2013-09-30 Sold Out -0.14%$30.906 - $47.97
($38.37)
$ 12.18-68%Sold Out0
SRPTAndreas Halvorsen 2013-03-31 Buy 0.15%$23.97 - $36.95
($28.83)
$ 12.18-58%New holding, 690731 sh.690,731
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
($28.83)
$ 12.18-58%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
($26.74)
$ 12.18-54%Add 184.13%226,429
SRPTJean-Marie Eveillard 2012-03-31 Sold Out $4.5 - $9.6
($6.06)
$ 12.18101%Sold Out0
SRPTJean-Marie Eveillard 2011-12-31 Reduce$3.24 - $6.54
($5.04)
$ 12.18142%Reduce -83.33%50,000
SRPTJean-Marie Eveillard 2011-09-30 Add$6.3 - $9.9
($7.92)
$ 12.1854%Add 50%300,000
SRPTJean-Marie Eveillard 2011-06-30 Buy $8.1 - $11.22
($9.66)
$ 12.1826%New holding, 200000 sh.200,000
SRPTGeorge Soros 2006-03-31 Buy 0.08%$24.54 - $50.45
($41.39)
$ 12.18-71%New holding, 308100 sh.308,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SRPT George Soros 2014-09-30325,0000.790.05-52.21%
Premium Most recent portfolio changes are included for Premium Members only!


SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.95-12.69view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.56-3.03view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-67.12view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.97-65.17view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.68-62.73view
Mahatme SandeshSenior Vice President, CFO 2013-08-20Buy5,000$31.1-60.84view
Price Ben GilDirector 2013-08-19Buy500$31.18-60.94view
CHASE ANTHONY RDirector 2013-06-14Buy10,000$38.5-68.36view
CHASE ANTHONY RDirector 2012-11-28Sell10,000$29.46-58.66view
CHASE ANTHONY RDirector 2012-11-14Sell10,000$25.7-52.61view

Press Releases about SRPT :

    Quarterly/Annual Reports about SRPT:

    News about SRPT:

    Articles On GuruFocus.com
    Ebola: Is The Cure Out There? Oct 14 2014 
    Insiders Are Buying Fate Therapeutics Oct 09 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Feb 16 2013 

    More From Other Websites
    Coverage initiated on Sarepta Therapeutics by RBC Capital Mkts Jan 23 2015
    INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the... Jan 20 2015
    BioMarin CEO Angers Sarepta CEO With Slides Comparing Trial Data Jan 16 2015
    Sarepta Starts Dosing in Duchenne Muscular Dystrophy Study - Analyst Blog Jan 15 2015
    Sarepta's CEO can reverse the company's downward trend with a stellar presentation tomorrow Jan 14 2015
    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Sarepta... Jan 14 2015
    Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in... Jan 14 2015
    Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen... Jan 14 2015
    Sarepta Therapeutics Announces First Patient Dosed in European Phase I/II Study of SRP-4053 in... Jan 14 2015
    Chimerix tackles Ebola outbreak Jan 13 2015
    Taking Stock: Winners and Losers, Stock of the Day Jan 12 2015
    Sarepta Therapeutics (SRPT) Stock Hits One-Year Low Today After Eteplirsen Update Jan 12 2015
    Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year Jan 12 2015
    Sarepta Therapeutics Falls Following 6-Minute Walk Test Results Jan 12 2015
    SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change... Jan 12 2015
    Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen... Jan 12 2015
    Sarepta Therapeutics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor... Jan 07 2015
    Sarepta Therapeutics to Present Company Overview at the 2015 33rd Annual J.P. Morgan Healthcare... Jan 05 2015
    Sarepta Therapeutics to Present Company Overview at the 2015 33rd Annual J.P. Morgan Healthcare... Jan 05 2015
    SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Sarepta... Jan 02 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK